Ligne de temps

01 janv. 2023
publication

Sec61 blockade therapy overrides resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma.

Lire plus
07 mars 2022
publication

The Sec61 translocon is a therapeutic vulnerability in multiple myeloma.

Lire plus
11 janv. 2022
news

New publication – The Sec61 translocon is a therapeutic vulnerability in multiple myeloma

Lire plus